IsoBev Inc. has purchased brewing equipment and hired staff for the brewing of hemp beer and the production of functional beverages to include hops, cannabinoids and terpenes for R&D and pilot projects. The Company is finalizing relationships with established brewing and beverage companies for commercial scale production and distribution.
VANCOUVER, British Columbia, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTC:ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global CBD leader and innovator is pleased to announce the progress of its months-long efforts to develop new hemp-based beers and functional beverages.
In May 2018, IsoBev Inc. (“IsoBev”), a wholly owned subsidiary of Isodiol, acquired a turn-key brewing system, including a 7-bbl brewhouse, four 15-bbl fermentation tanks, a 30-bbl fermentation tank, a 15-bbl brite tank, and a 30-bbl brite tank, which is expected to yield between 1,500 and 2,000 bbls of production per year. In addition, IsoBev acquired a 12-ounce bottling line and a 22-ounce bottling line, which could yield over 600,000 12-oz bottles and 25,000 12-oz bottle cases per year.
Certain hemp plant parts and hemp-derived ingredients are permitted by federal and state governments to be added to alcoholic beers, providing enhanced flavor and health and wellness benefits to the consumer, in addition to recreational use. Alternatively, functional beverages are intended to convey both flavor and health and wellness benefits to the consumer without the alcohol component or the burden of heightened regulatory compliance related to alcohol.
“IsoBev’s new brewing system is intended to serve a research and development function and produce commercial products for test markets with respect to alcoholic and non-alcoholic beers and functional beverages,” said Marcos Agramont, Isodiol’s CEO. “We believe there is a significant demographic within the existing beer, wine, and spirits and health and wellness consumer markets that is open to unique beverage experiences, with a particular interest in cannabinoid-rich carbonated beverages.”
Since acquiring its brewing equipment, IsoBev has been working with an established beer company on the West Coast to formulate these new beers and functional beverages. IsoBev, has also been in negotiations with an industry leading contract brewer with the capacity to fulfill all of its commercial-scale brewing needs nationally and internationally, including in all conventional can, bottle, and keg product formats.
Isodiol also is pleased to announce it has hired a lead brewer who will spearhead the implementation of these plans and work with Isodiol’s medical advisory board and product development team to maximize the health and wellness benefits of these novel products.
“The beverage industry is in a period of evolution, and hemp-derived products are beginning to play a big role in that evolution,” said Agramont. “Isodiol’s superior product development capacity and industry-leading quality cannabinoid ingredients make the Company a natural player in the beverage industry. We look forward to finalizing our relationship with a licensed alcohol brewing partner in the coming weeks, leveraging our partner distribution and contract manufacturing relationships, and bringing these novel products to the beverage market in 2018.”
For more information on Isodiol, please visit www.isodiol.com.
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical-grade pure, natural CBD and in the manufacturing and development of CBD consumer products.
Isodiol is the pioneer of many firsts in the CBD industry, including the commercialization of 99%+ pure, natural isolated CBD, micro-encapsulations, and nano-technology for the highest quality topical skin care and consumable products. Most recently, the Company received approval for its highest grade CBD to be designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, which was announced on April 26, 2018.
Isodiol’s growth strategy includes the development of over-the-counter (OTC) and pharmaceutical drugs, expanding its consumer products portfolio, and aggressively continuing international expansion into Latin America, Asia, and Europe.
Join Us On Facebook: https://www.facebook.com/IsodiolInternationalInc/
Twitter: @Isodiolintlinc
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.